India's drug regulator said on December 29 that it had inspected Marion Biotech's production facility and promised more action based on the probe report after the company's cough syrup was linked to the deaths of 18 children in Uzbekistan. A legal representative said Marion Biotech regretted the deaths and the company had halted production of the Doc-1 Max syrup. The drug regulator reviewed the company's Noida facility in Uttar Pradesh and is in regular touch with its Uzbek counterpart, the Indian Health Ministry said in a statement. To read the original story by Reuters, click here.
Indian Maker Of Syrup Linked To Uzbekistan Deaths Halts Production; Facility Inspected
The sale of Doc-1 Max has been suspended in Uzbekistan.